PMCF under MDR Annex XIV Part B: plan, evaluation report and PSUR
The MDR anchors the PMCF plan in two places at once: as Part B of Annex XIV in its own right, and as an element of the PMS plan under Annex III, where only a justification as to why a PMCF is not applicable may take its place. Its results have to appear in three documents, the clinical evaluation report, the risk management and, from class IIa upward, the periodic safety update report, and where a notified body is involved, it reads all three.
Entourage Editorial Team
In brief
What MDR Annex XIV Part B requires of the PMCF plan (Sections 6.1 and 6.2) and the PMCF evaluation report (Sections 7 and 8), what the templates MDCG 2020-7 and 2020-8 add, which intervals Article 61(11) and Article 86 set, why MDCG 2020-7 recommends sourcing the evidence from the device itself, and what applies to legacy devices.
"Our PMS plan covers that." The sentence comes up in many preparations for a surveillance audit, and it is half right. Annex III Section 1(b) MDR requires the post-market surveillance plan to cover "a PMCF plan as referred to in Part B of Annex XIV, or a justification as to why a PMCF is not applicable". So the PMCF does belong in the PMS plan. What is written there, however, has to meet the requirements of Annex XIV Part B in its own right, and those are what the notified body reviews.
The regulation describes PMCF as "a continuous process that updates the clinical evaluation" (Annex XIV Part B Section 5); under Article 10(3), manufacturers conduct a clinical evaluation "including a PMCF". How to choose a method and build a program is explained on our PMCF page. This article follows the data: which documents they flow into, at which intervals, and where the chain breaks.
Three documents, one data set
The manufacturer analyzes the findings of the PMCF and documents them in a PMCF evaluation report "that shall be part of the clinical evaluation report and the technical documentation" (Annex XIV Part B Section 7). Its conclusions "shall be taken into account for the clinical evaluation referred to in Article 61 and Part A of this Annex and in the risk management referred to in Section 3 of Annex I" (Section 8). And the periodic safety update report under Article 86(1), which manufacturers of class IIa, IIb and III devices prepare, sets out "the main findings of the PMCF" throughout the lifetime of the device (point (b)). The same data therefore appear in three places. MDCG 2022-21 provides a section in the PSUR for this, "Specific Post-Market Clinical Follow-up (PMCF) Information", which refers to the main findings and, when available, to the conclusions documented in the evaluation report.
The notified body reads all of it. Under Annex VII Section 4.8, its procedures must enable it to "decide, based on the results of its assessment of the clinical evaluation and risk management, whether the post-market surveillance plan, including the PMCF plan, is adequate". MDCG 2020-7 adds that the notified body's assessment of the clinical evaluation also covers the manufacturer's procedures and documentation of the PMCF, "as well as the justification in relation to non-performance of PMCF". A plan that announces a registry study, a report that does not mention it, and a PSUR that gets by without those data tell three stories, read by the same body.
The plan: Sections 6.1 and 6.2, plus MDCG 2020-7
Section 6.1 names five aims: confirming safety and performance "throughout its expected lifetime", identifying previously unknown side-effects and monitoring the known ones, identifying and analyzing emergent risks "on the basis of factual evidence", ensuring the continued acceptability of the benefit-risk ratio, and identifying systematic misuse or off-label use. Section 6.2 sets the minimum content, eight items:
- (a) the general methods, such as clinical experience, feedback from users and scientific literature,
- (b) the specific methods, such as suitable registers or PMCF studies,
- (c) a rationale for the appropriateness of those methods,
- (d) a reference to the clinical evaluation report and to the risk management referred to in Annex I Section 3,
- (e) the specific objectives of the PMCF,
- (f) an evaluation of the clinical data relating to equivalent or similar devices,
- (g) reference to relevant CS, harmonized standards and guidance on PMCF,
- (h) "a detailed and adequately justified time schedule" for PMCF activities.
The template MDCG 2020-7 of April 2020 arranges this into Sections A to G and gets more specific than the regulation in three places. The timelines of the activities "shall be also defined quarterly or at least yearly" (Section C). The rationale for the method requires a statistical justification for the expected quality of outcomes; retrospective surveys without that justification "are not acceptable" (Section C). And the reference under point (d) becomes, in Section D, a table with "Clinical Evaluation Report (date and version)" and "Risk Management File (date and version)" together with the items to be followed up from each. A plan without the date and version of these two documents cannot be read against them.
The report: Sections 7 and 8, plus MDCG 2020-8
For the evaluation report, MDCG 2020-8, also of April 2020, sets the structure. Section E, "Impact of the results on the technical documentation", is where the chain is held together: for the clinical evaluation report and the risk management file, each with date and version, the manufacturer records what was analyzed and what is to be reported in the updated document. If the manufacturer ticks the box that nothing was considered, the template expects an explanation. Section G draws the conclusion, relates it to the aims of the plan and states whether preventive or corrective measures are needed, which the manufacturer then implements under Section 8. The report is thus finished only once the risk management file and the clinical evaluation report record what was taken over from it; how the file is structured is covered in Risk Management.
The rhythm nobody writes in the calendar
The intervals sit in two articles. Under Article 61(11), the clinical evaluation and its documentation are updated throughout the life cycle with the data from the PMCF plan and the PMS plan; for class III devices and implantable devices, the PMCF evaluation report and, if indicated, the summary of safety and clinical performance are updated "at least annually". Under Article 86(1), manufacturers of class IIb and class III devices update the PSUR "at least annually", manufacturers of class IIa devices "when necessary and at least every two years". For class III and implantable devices, Article 86(2) further provides that the manufacturer submits the report to the notified body by means of the electronic system referred to in Article 92, and that the notified body reviews it and adds its evaluation to that system. Article 123(3)(d) defers this route through the electronic system until that EUDAMED module becomes mandatory (status of the modules: EUDAMED readiness). Until then, under MDCG 2021-1 Rev.1 and MDCG 2022-21, the report goes to the notified body by other appropriate means; under MDCG 2021-1 Rev.1, the notified body provides its evaluation to the manufacturer. For a class III implant, two annual deadlines therefore run on the same data. Whoever aligns them has the PMCF report ready when the PSUR is due to cite it; whoever plans them separately cites last year's status in the PSUR.
Two traps
"No PMCF needed." Annex III Section 1(b) expressly allows the justification. For implantable devices and class III devices, however, the regulation presupposes PMCF data: Article 61(11) requires the annually updated PMCF evaluation report. Where clinical investigations are also waived under Article 61(4) because the device was designed by modifying a device already marketed by the same manufacturer, its equivalence has been demonstrated and confirmed by the notified body, and the clinical evaluation of the marketed device suffices (Article 61(5) opens this route, under conditions, for equivalence with another manufacturer's device as well), "the notified body shall check that the PMCF plan is appropriate and includes post market studies to demonstrate the safety and performance of the device". In these classes, a justification of "not applicable" therefore always has to argue against Article 61(11), and in a waiver case under Article 61(4) against a second express provision as well. For devices that Article 61(6) exempts from the requirement to perform clinical investigations, that second provision does not apply; Delegated Regulation (EU) 2026/1451 has considerably extended the list in Article 61(6)(b), adding among others dental implants, pacing wires and leads, and bone substitutes. That is our reading; the line is drawn by the text of the regulation.
Third-party data as your own evidence. Section 6.2(f) requires an evaluation of the clinical data relating to equivalent or similar devices, and some plans lean mainly on it. MDCG 2020-7 Section E draws the line as a recommendation ("should"): "PMCF data intended to demonstrate continuing safety and performance should be sourced from the device under evaluation." According to the template, third-party data may be used, for example, to update the information relating to the state of the art and to identify relevant safety outcomes; the selected devices have to be consistent throughout the technical documentation.
Legacy devices: the MDD certificate does not shield you from PMCF
For devices still being placed on the market under Article 120(3a) with a certificate issued under the directives, or under Article 120(3b) with a declaration of conformity drawn up before May 26, 2021 (no notified body involved so far), Article 120(3d) provides that the requirements of the regulation relating to post-market surveillance apply "in place of the corresponding requirements in Directives 90/385/EEC and 93/42/EEC". MDCG 2020-6 draws the consequence: legacy devices "are therefore not exempted from the additional requirements in MDR concerning PMS, including PMCF." For in vitro diagnostics the parallel provision is PMPF under IVDR Annex XIII Part B. What PMCF data can contribute to health technology assessment and reimbursement is covered in our article on real-world evidence.
Three check questions for your own documentation
The selection is ours.
- Does the PMCF plan name the clinical evaluation report and the risk management file with date and version, and are those the versions the latest report updated in its Section E?
- Does the PSUR, under the main findings of the PMCF, say the same as Section G of the evaluation report, and does the cited report carry a date from the current reporting period?
- Do the data with which the plan intends to confirm safety and performance come from the device itself, or is the section on equivalent devices carrying that load?
We support building the program in PMCF, the overarching system in Post-Market Surveillance, and feeding the data back into Clinical Evaluation.
Image notice: The images in this article were generated using artificial intelligence. They do not depict real people, places, or events.
Relevant for your project?
Similar questions in your current project?
In a first call we clarify what is specifically relevant for your situation, without obligation.
Request a call →Regulations & standards considered
- Regulation (EU) 2017/745 (MDR), Art. 10(3), Art. 61(4) to (6) and (11), Art. 83(3), Art. 84, Art. 86, Art. 120(3a), (3b) and (3d), Art. 123(3)(d)
- MDR Annex III Section 1, Annex VII Section 4.8, Annex XIV Part B Sections 5 to 8
- MDCG 2020-7 (PMCF plan template), MDCG 2020-8 (PMCF evaluation report template), MDCG 2020-6 (sufficient clinical evidence for legacy devices), MDCG 2022-21 (PSUR), MDCG 2021-1 Rev.1 (alternative solutions until EUDAMED is fully functional)
- Regulation (EU) 2017/746 (IVDR), Annex XIII Part B (PMPF), by reference only
FAQ
Frequently asked questions
Related expertise
PMCF Services →
Building the PMCF plan, choosing the method and writing the PMCF evaluation report under Annex XIV Part B
Post-Market Surveillance →
The PMS system under Articles 83 to 86, in which the PMCF plan sits under Annex III Section 1
Clinical Evaluation →
Updating the clinical evaluation under Article 61(11) with the data from PMCF
Risk Management →
The risk management file into which the PMCF evaluation report flows back under Section 8
Medical Device Vigilance →
The reactive strand next to proactive PMCF: incidents, trend reporting, corrective actions
Related projects
All case studies →Sources
- Regulation (EU) 2017/745 (MDR), consolidated version 02017R0745-20260719, full text DE/EN/IT via the Publications Office Cellar: Art. 10(3), Art. 61(4) to (6) (Art. 61(6)(b) as amended by Delegated Regulation (EU) 2026/1451) and (11), Art. 83(3), Art. 84, Art. 86(1) to (3), Art. 120(3a), (3b) and (3d), Art. 123(3)(d), Annex III Section 1, Annex VII Section 4.8, Annex XIV Part B Sections 5 to 8
- MDCG 2020-7, Post-market clinical follow-up (PMCF) Plan Template, April 2020, Introduction and Sections C, D, E, G: https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_7_guidance_pmcf_plan_template_en_0.pdf
- MDCG 2020-8, Post-market clinical follow-up (PMCF) Evaluation Report Template, April 2020, Introduction and Sections C to G: https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_8_guidance_pmcf_evaluation_report_en_0.pdf
- MDCG 2020-6, Guidance on sufficient clinical evidence for legacy devices, April 2020, Section 5: https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_6_guidance_sufficient_clinical_evidence_en_0.pdf
- MDCG 2022-21, Guidance on periodic safety update report (PSUR) according to Regulation (EU) 2017/745, December 2022, section "Specific Post-Market Clinical Follow-up (PMCF) Information" and section 5.4 (submission in the absence of EUDAMED)
- MDCG 2021-1 Rev.1, guidance on administrative practices and alternative technical solutions until EUDAMED is fully functional, row on Article 86: https://health.ec.europa.eu/document/download/ea0369a7-d86c-465e-9a54-0c0dfb01bc84_en?filename=2021-1_guidance-administrative-practices_en.pdf
- Regulation (EU) 2017/746 (IVDR), consolidated version 02017R0746-20250110, Annex XIII Part B (existence of the parallel provision checked only)
Related insights
All insights →Your project
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Your inquiry goes to our team, which brings in the subject-matter experts as needed.
Prefer direct? +39 02 8904 1000
contact@theentourage.it
- Reply usually within one working day
- 3 locations: DE · CH · IT · projects in the US too
- 100% life sciences





